Australia consults on fees under new biologicals framework
This article was originally published in SRA
Australia's Therapeutic Goods Administration has proposed fee rates for evaluating applications under the new biologicals framework that covers human cell and tissue therapy products (HCTs)1-3. The framework was signed into law earlier this year4 and will enter into force on 31 May 2011.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.